About Us
Markets
Research
Services
NRI Corner
Fund Transfer
Select Link
MF Back Office-SB
MF Back Office-Client
Back Office - Client
Back Office - Sub Brokers
Backoffice – Family Login
Webmail
SPEEDe Login
BSE STAR MF
Branch Login
Create Account
About Us
Markets
Research
Services
Portfolio
NRI Cornor
Fund Transfer
Company Snapshot
Read it, Learn it and Do it for your investment Needs
Equity
Derivatives
Currency
Mutual Fund
IPO
Daily market Tracker
Market Analysis
News Analysis
Company profile
Corporate Actions
Other Market
ETF market Watch
Daily market Tracker
Daily market Tracker
Market Analysis
News Analysis
Company profile
Corporate Actions
Other Market
ETF market Watch
Get Quotes
Company Snapshot
Company Background
Board Of Directors
Peer Comparison
+13 more
Score Board
Directors Report
MF Holding
Charts
Company News
History
Monthly High Low
Balance Sheet
Technicals
Profit & Loss
Quarterly Results
Key Financial Ratios
Deliverable Volumes
Share Holdings Pattern
Bonus Issue
Demergers
Dividend
Mergers
Right Issues
Split Of Facevalue
Company Profile
Get Quotes
Company Snapshot
Company Background
Board Of Directors
Peer Comparison
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Holdings Pattern
Charts
Company News
Directors Report
History
MF Holdings
Profit & Loss
Monthly High Low
Technicals
Deliverable Volumes
Company News Details
Glenmark Pharmaceuticals Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code:
532296
NSE Symbol:
GLENMARK
P/E :
35.29
ISIN Demat:
INE935A01035
Div & Yield %:
0.11
EPS :
61.81
Book Value:
868.32
Market Cap (Rs. Cr.):
61,563.52
Face Value :
1
Board of Glenmark Pharmaceuticals recommends final dividend
Back
(24 May 2025)
Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 23 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.